Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

BMC Pulmonary Medicine

Case Report

Stefan Kluge¹  Carsten Bokemeyer²  Hans Klose²  Hans Jörg Baumann²  Jan K Hennigs³  Tim H Brümmendorf⁴  Friedemann Honecker⁴  Gunhild Keller⁴ 

[1] Centre for Pulmonary Hypertension, University Medical Centre Hamburg - Eppendorf, 20246, Hamburg, Germany;Department of Critical Care Medicine, University Medical Centre Hamburg - Eppendorf, 20246, Hamburg, Germany;Centre for Pulmonary Hypertension, University Medical Centre Hamburg - Eppendorf, 20246, Hamburg, Germany;Department of Internal Medicine II - Oncology, Haematology, BMT and Pneumology, University Medical Centre Hamburg - Eppendorf, 20246, Hamburg, Germany;Centre for Pulmonary Hypertension, University Medical Centre Hamburg - Eppendorf, 20246, Hamburg, Germany;Department of Internal Medicine II - Oncology, Haematology, BMT and Pneumology, University Medical Centre Hamburg - Eppendorf, 20246, Hamburg, Germany;Department of Critical Care Medicine, University Medical Centre Hamburg - Eppendorf, 20246, Hamburg, Germany;Department of Internal Medicine II - Oncology, Haematology, BMT and Pneumology, University Medical Centre Hamburg - Eppendorf, 20246, Hamburg, Germany;

关键词: Pulmonary hypertension;    drug induced;    antiproliferative therapy;    leukaemia;    side effects;   

DOI  :  10.1186/1471-2466-11-30

 received in 2010-11-02, accepted in 2011-05-23,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundPulmonary hypertension (PH) is a life-threatening disease with poor prognosis. Encouraging efforts have been made to target the main vasoproliferative aspects of the disease. Promising emerging therapeutics are tyrosine kinase inhibitors such as imatinib.Case presentationHere, we discuss the relevance of previously published cases and add another well-characterised patient who developed pre-capillary PH under long-term therapy with the multi-tyrosine kinase inhibitor dasatinib approved for therapy of chronic myeloic leukaemia (CML) and Philadelphia chromosome positive acute lymphocytic leukaemia (mean time of all patients on dasatinib: 26 months). Hence, we discuss the possibility of dasatinib itself causing PH after long-term therapy and turn specialist's attention to this possible severe side effect.At present, the true incidence of dasatinib-associated PH remains illusive and systematic data regarding haemodynamics are missing.ConclusionWe therefore recommend systematic screening of dasatinib-treated patients for pulmonary hypertension and subsequent collection of haemodynamic data.

【 授权许可】

Unknown   
© Hennigs et al; licensee BioMed Central Ltd. 2011. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.